Clinical Trial: Monitoring MRD in Multiple Myeloma in Serum by Mass Spectrometry

U.S., July 9 -- ClinicalTrials.gov registry received information related to the study (NCT07691034) titled 'Monitoring MRD in Multiple Myeloma in Serum by Mass Spectrometry' on June 23.

Brief Summary: Multiple myeloma (MM) is a severe plasma cell cancer caused by proliferation and accumulation of malignant plasma cells in the bone marrow. Novel therapies have improved responses and survival considerably. Recently, it was shown that achieved and sustained minimal residual disease (MRD) negativity is the best predictor for long-term disease-free and overall survival. Achieving and maintaining MRD negativity will therefore be the new treatment goal for patients with MM. Two methods are established for MRD analysis; next-generation flowcytomet...